ArticleCureus2026
Gout Flare in Hospitalized Patients: Risk Factors and the Impact of Allopurinol Management.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Gout flares are a common and preventable complication among hospitalized patients. Changes in urate-lowering therapy, particularly allopurinol, may influence flare risk. Objective To evaluate risk factors for inpatient gout flares and the impact of allopurinol management during hospitalization. Methods This retrospective cohort study included 211 hospitalized patients with gout. Patients were categorized based on allopurinol exposure (continued, discontinued, resumed/initiated, or never used). The primary outcome was gout flare during hospitalization. Univariate and multivariable analyses were performed. Results Among 211 patients, 25 (11.8%) developed gout flares. Patients with flares had higher serum uric acid levels (10.1±2.3 vs. 9.1±2.0 mg/dL, p=0.03), higher prevalence of chronic kidney disease (52% vs. 35%, p=0.04), and greater diuretic use (36% vs. 18%, p=0.02). Allopurinol discontinuation (odds ratio (OR), 6.8; 95% confidence interval (CI), 2.8-16.5; p=0.001) and initiation/resumption (OR 5.9, 95% CI 2.1-16.8, p=0.002) were independently associated with increased flare risk. Conclusion In hospitalized patients, modification of allopurinol therapy is strongly associated with gout flares. Maintaining stable urate-lowering therapy may reduce preventable inpatient flares.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.